---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-023001"
form_type: "8-K"
ticker: "BCPC"
cik: "0000009326"
company_name: "BALCHEM CORP"
filed_at: "2022-06-15T23:59:59+00:00"
generated_at: "2026-06-25T01:48:55.021995+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Balchem to acquire Kappa Bioscience for $338M; accretive to EPS in 2022

## Summary
- Enterprise value of NOK 3.175B (~$338M); EV/EBITDA multiple of 18x on 2022 forecast.
- Kappa's FY2022 forecast revenues ~NOK 500M (~$53M) with strong growth and margin profile.
- Additional earn-out potential of 0% to 16% of enterprise value in 2024 based on performance.
- Closing expected Q2 2022; financed via existing revolver and cash on hand.
- Deal expected to be accretive to Balchem's adjusted EPS in 2022.

## SEC filing metadata
- accession: 0001140361-22-023001
- form_type: 8-K
- ticker: BCPC
- cik: 0000009326
- company_name: BALCHEM CORP
- filed_at: 2022-06-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/9326/000114036122023001/0001140361-22-023001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/9326/000114036122023001/brhc10038776_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-023001
- JSON: https://secwatch.observer/filing/0001140361-22-023001.json
- Plain text: https://secwatch.observer/filing/0001140361-22-023001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.